A dermatologist explores the underlying type 2 inflammatory pathway linking atopic dermatitis and prurigo nodularis, highlighting specific biomarkers that aid in identifying patients with type 2 inflammation-driven dermatologic conditions.
What role does type 2 inflammation play in the connection between AD and PN?
What specific biomarkers can be used to identify patients with dermatologic conditions driven by type 2 inflammation, and how reliable are these biomarkers?